The following is a summary of the PetMed Express, Inc. (PETS) Q4 2024 Earnings Call Transcript:

Financial Performance:

• For Q4 2024, PetMed Express reported a revenue of $66.5 million, reflecting a 6.6% increase year-over-year, primarily driven by the acquisition of PetCareRx.

• Gross profit margin for the fourth quarter was listed at 27.3%, experiencing a slight decrease from 27.9% in the same quarter last year.

• The company reported a net loss of $5 million or $0.25 per diluted share, compared to a net loss of $200,000 or $0.01 per diluted share in the prior year's same quarter.

Business Progress:

• PetMed Express is focusing on integrating its PetMeds and PetCareRx brands to create a more streamlined operation.

• The company is enhancing key relationships with suppliers, improving inventory management, and taking steps to reduce operational costs through consolidation and enhanced technology use.

• The company appointed new members to key roles including Chief Marketing Officer and Chief Digital and Technology Officer to drive forward technological improvements and marketing strategies.

Opportunities:

• The continued growth in the pet care sector, particularly in medication, food, and health services, presents significant opportunities for PetMed Express.

• PetMed Express is expanding its digital capabilities and automation to enhance efficiencies and customer interactions.

Risks:

• There was no explicit mention of specific risks facing the company in the forward-looking statements.

More details: PetMed Express IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.